50289-14-0

Basic information

• Product Name: 4-(nitromethyl)tetrahydropyran-4-ol
• CAS NO: 50289-14-0
• Molecular Formula: C₆H₁₁NO₄
• Molecular Weight: 161.1558
• Mol File: 50289-14-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 333.526°C at 760 mmHg
• Flash Point: 155.511°C
• Density: 1.271g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.494
• CAS DataBase Reference: 4-(nitromethyl)tetrahydropyran-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(nitromethyl)tetrahydropyran-4-ol(50289-14-0)
• EPA Substance Registry System: 4-(nitromethyl)tetrahydropyran-4-ol(50289-14-0)

Safety Data

• Hazardous Substances Data: 50289-14-0(Hazardous Substances Data)

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 75-52-5 nitromethane 

Downstream Products

• 1426411-50-8 6-(3,4-dichloro-phenyl)-pyrimidine-4-carboxylic acid (4-hydroxy-tetrahydro-pyran-4-ylmethyl)-amide 
• 783303-73-1 4-(aminomethyl)tetrahydro-2H-pyran-4-ol 

Relevant articles and documents

QUINAZOLINE COMPOUND FOR EGFR INHIBITION

Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.

KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.